Needham & Company LLC restated their buy rating on shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) in a research report report published on Friday. Needham & Company LLC currently has a $26.00 price objective on the stock.

“Zealand mgmt hosted a conference call today to discuss the sale of its lixisenatide revenue stream to $205M cash. All royalties and nearly all milestone payments from Sanofi will now be diverted to Royalty Pharma. Zealand retained its right to receive a milestone payment of $10-15M from Sanofi in 2020. Net proceeds to Zealand will be approximately $150M after factoring for redemption of $24.7M royalty bond and a 13.5% payment to Alkermes. Considering our modest sales projections for lixisenatide products, we believe the transaction is priced fairly. Zealand ended 2Q18 w/ $73.1M cash. Near-term milestones include results from dasiglucagon Phase 3 trial in Acute Severe Hypoglycemia as well as Phase 3 trial initiations for glepaglutide in and dasiglucagon in Congenital Hyperinsulinism.”,” Needham & Company LLC’s analyst wrote.

ZEAL stock traded up $1.69 during trading on Friday, reaching $16.06. 115,235 shares of the stock were exchanged, compared to its average volume of 4,638. ZEALAND PHARMA/S has a twelve month low of $12.01 and a twelve month high of $20.37.

An institutional investor recently raised its position in ZEALAND PHARMA/S stock. Farallon Capital Management LLC increased its position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) by 33.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 865,000 shares of the company’s stock after buying an additional 215,000 shares during the quarter. Farallon Capital Management LLC owned 2.81% of ZEALAND PHARMA/S worth $12,992,000 at the end of the most recent quarter. 11.32% of the stock is owned by institutional investors.

ZEALAND PHARMA/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Recommended Story: Asset Allocation Models, Which is Right For You?

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with's FREE daily email newsletter.